Author
Tango Therapeutics (United States)ORCID 0000-0001-5501-0212Unclaimed ORCID profile · follow to get notified of new preprints
4 papers
Recent·Most cited
Silvia Fenoglio, Yi Yu, James Tepper…·Teng Teng
This paper introduces CRISPR-StAR, an in vivo CRISPR screening platform with improved normalization and analysis tools, showing it can identify tumor suppressor gene effects not observable in vitro.
Matthew R. Tonini, Samuel R. Meier, Shangtao Liu…·Kimberly J. Briggs
This paper identifies a splicing signature caused by PRMT5 inhibition in MTAP-deleted cancers, showing histology-agnostic splicing changes and potential as a biomarker for PRMT5 inhibitor activity.
Hongxiang Zhang, Matthew R. Tonini, Lauren Catherine M. Martires…·Teng Teng
The paper identifies HBS1L as a synthetic lethal target in FOCAD-deleted cancer through combinatorial CRISPR screens and validates its dependency via genetic manipulation and in vivo experiments.
Peter C. DeWeirdt, Kendall R Sanson, Annabel K. Sangree…·John G. Doench
This paper optimizes AsCas12a for combinatorial genetic screens in human cells by improving on-target and off-target activity and enabling higher-order multiplexing.